Toxicity of argatroban overdose in a 65-year-old man [3]

American Journal of Hematology

Volumn 79, Issue 3, 2005, Pages 248-249

  Knoblauch, Roland ^a   Pollak, Eleanor S ^a   Russell, J Eric ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; HEPARIN;

AGED; CASE REPORT; DRUG HALF LIFE; DRUG METABOLISM; DRUG OVERDOSE; HEMODYNAMIC MONITORING; HUMAN; ISCHEMIC HEART DISEASE; LETTER; LIVER DYSFUNCTION; MALE; MITRAL VALVE REPLACEMENT; PRIORITY JOURNAL; THROMBOCYTOPENIA; VALVULAR HEART DISEASE;

AGED; HEART VALVE DISEASES; HUMANS; MALE; MEDICAL ERRORS; OVERDOSE; PIPECOLIC ACIDS; THROMBOCYTOPENIA;

EID: 22044453384     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20335     Document Type: Letter

References (4)

1. Argatroban package insert. Philadelphia, PA: GlaxoSmithKline; 2004.
2. Ueki Y, Matsumoto K, Kizaki Y, et al. Argatroban increases nitric oxide levels in patients with peripheral arterial obstructive disease: placebo-controlled study. J Thromb Thrombolysis 1999;8:131-137.
3. Winn MJ, Jain K, Ku DD. Argatroban and inhibition of the vasomotor actions of thrombin. J Cardiovasc Pharmacol 1993;22:754-760.
4. Schrodter HM, Glusa E. The thrombin inhibitor argatroban does not influence the endothelium-dependent relaxant and contractile responses of isolated rabbit carotid arteries. Exp Toxicol Pathol 2003;54:499-504.